Tower Research Capital LLC (Trc) Xilio Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,207 shares of XLO stock, worth $3,197. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,207
Previous 11,153
62.28%
Holding current value
$3,197
Previous $12,000
75.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding XLO
# of Institutions
33Shares Held
12.6MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA3.79MShares$2.88 Million0.74% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3MShares$2.28 Million0.09% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.1 Million20.01% of portfolio
-
Morgan Stanley New York, NY1.11MShares$845,6820.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$685,9230.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $20.9M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...